Portfolio of Diagnostic Panels

About Novelna

Novelna is an early-stage biotech company developing a proprietary AI-powered proteomics platform for biomarker discovery and diagnostic test development. The company's core focus is on creating multi-cancer early detection (MCED) tests and other diagnostics aimed at asymptomatic populations, addressing a critical unmet need where effective screening is currently lacking. With a team combining expertise in medicine, proteomics, AI, and business development, Novelna is building a broad pipeline of tests while emphasizing cost reduction and scalability. The company is privately held and appears to be in a pre-revenue, pre-clinical development stage.

Therapeutic Areas